The Canadian Ophthalmology Society's adaptation of the Medically Necessary Time-sensitive Surgical Procedures triage and prioritization tool

Salina Teja, MD Colin Mann, MD Phil Hooper, MD Yvonne Buys, MD Vivian T. Yin, MD, MPH

Accepted Aug. 12, 2020

Correspondence to:

V.T. Yin Faculty of Medicine University of British Columbia 2550 Willow St Vancouver BC V5Z 3N9 viviany@me.com

DOI: 10.1503/cjs.012120

SUMMARY

At the start of the coronavirus disease 2019 (COVID-19) pandemic, hospitals and ambulatory surgical centres significantly decreased elective surgical procedures to facilitate capacity for in-hospital beds, preserve personal protective equipment (PPE), preserve anesthetic medications and limit spread of infection. Non-COVID-19-related ophthalmic disease continues to affect vision, and it is anticipated that the backlog of elective surgeries will require months to years to resolve. The delivery of ophthalmic surgical care in a prioritized, systematic and transparent way is vital to manage the surgical backlog while minimizing vision loss and consequent disability in the Canadian population. The Canadian Ophthalmology Society (COS) has modified the published Medically Necessary, Time Sensitive (MeNTS) Procedures scoring system to be applicable to all subspecialties within ophthalmology. This case prioritization process integrates medical necessity, consideration of resource preservation with risk of COVID-19 exposure, and factors unique to eye care. It provides guidance to Canadian ophthalmologists to facilitate decision making in triaging elective procedures.

t the start of the coronavirus disease 2019 (COVID-19) pandemic, hospitals and ambulatory surgical centres significantly decreased elective surgical procedures in an effort to allow for in-patient bed capacity, preserve personal protective equipment (PPE), preserve anesthetic medications and limit the risk of spread of infection. Ophthalmology experienced one of the largest decreases in clinical and surgical volume, averaging at -81% compared with an average across all service lines of -54.5%.¹ Two of the top 3 conditions that experienced the largest drop in encounters were cataracts (-97%) and glaucoma (-88%). Despite this reduction in patient encounters, non-COVID-19-related ophthalmic disease continues to affect vision, and it is anticipated that the backlog of elective surgeries required to treat these conditions will require months to years to resolve. These elective surgeries address visual impairment (VI) that affects patients' productivity, mental health, risk of falls, childhood development and quality of life.² The effect of VI is not limited to the individual, but has a wider impact on patients' families and society as a whole. The delivery of ophthalmic surgical care in a prioritized, systematic and transparent way is vital to manage the surgical backlog while minimizing permanent vision loss and consequent disability in the Canadian population.

In the prepandemic era, clinical reasoning provided the construct for decision making between surgeons and patients to undergo elective surgery. Case prioritization at the hospital level integrated the surgeon's assessment of medical necessity and time sensitivity with available operating room (OR) resources. In the COVID-19 pandemic era, however, appropriate management of OR resources in the face of a large backlog of deferred surgical cases now demands a case prioritization process that integrates medical

necessity with risk of COVID-19 exposure to both patients and the health care team as well as the use of health care resources like PPE, anesthetic medications and personnel. To this end, the Canadian Ophthalmology Society (COS) has adopted a framework originally

published in the *Journal of the American College of Surgeons* — the Medically Necessary, Time Sensitive (MeNTS) Procedures scoring system.³ The original validated tool was created through a review of the outcomes data regarding medical and perioperative outcomes of patients

OR time, min Surgical team size, <i>n</i> Estimated LOS Need for GA ilability & acceptability/ stiveness of nonsurgical treatment option** that falls below functional needs** sease process causes reversible vision loss or essive disease with 6-wk delay of 6-wk delay in increase I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of noperative treatment npared with surgery** Age, yr	< 30 1 Outpatient No None available or high SE Monocular patient Never reversible Extremely high Significantly worse Not applicable/ significantly worse	30–60 2 < 23 h Available but < 40% as effective as surgery or moderate SE Difficulty with ADLs or significant impact on development Partially reversible, central-involving High Worse Somewhat worse	60–120 3 24–48 h Available and 40% to 60% as effective as surgery Below driving/ occupati onal requirements or moderate impact on development Partially reversible, non-central- involving Moderate Moderately worse Equivalent	120–180 4 ≤ 3 d Yes Available and 60% to 95% as effective as surgery, low risk of SE Approaching driving/occupati onal requirements or minimal impact on development Low Slightly worse Somewhat better	≥180 > 4 > 4 d Available and equally effectiv No functional limitation or impact on development Always reversible Extremely low or none No worse Significantly better
Estimated LOS Need for GA ilability & acceptability/ triveness of nonsurgical treatment option** that falls below functional needs** sease process causes reversible vision loss or assive disease with 6-wk delay to 6 6-wk delay in increase I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of moperative treatment mpared with surgery**	Outpatient No None available or high SE Monocular patient Never reversible Extremely high Significantly worse Not applicable/ significantly	< 23 h Available but < 40% as effective as surgery or moderate SE Difficulty with ADLs or significant impact on development Partially reversible, central-involving High Worse	24–48 h Available and 40% to 60% as effective as surgery Below driving/ occupati onal requirements or moderate impact on development Partially reversible, non-central- involving Moderate Moderately worse	≤ 3 d Yes Available and 60% to 95% as effective as surgery, low risk of SE Approaching driving/occupati onal requirements or minimal impact on development Low	> 4 d Available and equally effectiv No functional limitation or impact on development Always reversible Extremely low or none No worse Significantly
Need for GA ilability & acceptability/ tiveness of nonsurgical treatment option** that falls below functional needs** sease process causes reversible vision loss or assive disease with 6-wk delay to 6 6-wk delay in increase I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of inoperative treatment npared with surgery**	No None available or high SE Monocular patient Never reversible Extremely high Significantly worse Not applicable/ significantly	Available but < 40% as effective as surgery or moderate SE Difficulty with ADLs or significant impact on development Partially reversible, central-involving High Worse	Available and 40% to 60% as effective as surgery Below driving/ occupati onal requirements or moderate impact on development Partially reversible, non-central- involving Moderate Moderately worse	Yes Available and 60% to 95% as effective as surgery, low risk of SE Approaching driving/occupati onal requirements or minimal impact on development Low Slightly worse	Available and equally effective No functional limitation or impact on development Always reversible Extremely low or none No worse Significantly
 ilability & acceptability/ tiveness of nonsurgical treatment option** that falls below functional needs** sease process causes reversible vision loss or passive disease with 6-wk delay cof 6-wk delay in increase I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of inoperative treatment inpared with surgery** 	None available or high SE Monocular patient Never reversible Extremely high Significantly worse Not applicable/ significantly	< 40% as effective as surgery or moderate SE Difficulty with ADLs or significant impact on development Partially reversible, central-involving High Worse	40% to 60% as effective as surgery Below driving/ occupati onal requirements or moderate impact on development Partially reversible, non-central- involving Moderate Moderately worse	Available and 60% to 95% as effective as surgery, low risk of SE Approaching driving/occupati onal requirements or minimal impact on development Low Slightly worse	equally effective No functional limitation or impact on development Always reversible Extremely low or none No worse Significantly
tiveness of nonsurgical treatment option** that falls below functional needs** sease process causes reversible vision loss f significant vision loss or essive disease with 6-wk delay to 6 6-wk delay in increase I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of moperative treatment npared with surgery**	or high SE Monocular patient Never reversible Extremely high Significantly worse Not applicable/ significantly	< 40% as effective as surgery or moderate SE Difficulty with ADLs or significant impact on development Partially reversible, central-involving High Worse	40% to 60% as effective as surgery Below driving/ occupati onal requirements or moderate impact on development Partially reversible, non-central- involving Moderate Moderately worse	to 95% as effective as surgery, low risk of SE Approaching driving/occupati onal requirements or minimal impact on development Low Slightly worse	equally effective No functional limitation or impact on development Always reversible Extremely low or none No worse Significantly
needs** sease process causes reversible vision loss f significant vision loss or essive disease with 6-wk delay cof 6-wk delay in increase l difficulty, surgical risk, or of additional intervention //D-19 exposure risk of inoperative treatment inpared with surgery**	patient Never reversible Extremely high Significantly worse Not applicable/ significantly	or significant impact on development Partially reversible, central-involving High Worse	occupati onal requirements or moderate impact on development Partially reversible, non-central- involving Moderate Moderately worse	driving/occupati onal requirements or minimal impact on development Low Slightly worse	limitation or impact on development Always reversible Extremely low or none No worse Significantly
f significant vision loss f significant vision loss or essive disease with 6-wk delay cof 6-wk delay in increase I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of noperative treatment npared with surgery**	reversible Extremely high Significantly worse Not applicable/ significantly	central-involving High Worse	reversible, non-central- involving Moderate Moderately worse	Slightly worse	reversible Extremely low or none No worse Significantly
c of 6-wk delay in increase I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of noperative treatment npared with surgery**	high Significantly worse Not applicable/ significantly	Worse	Moderately worse	Slightly worse	or none No worse Significantly
I difficulty, surgical risk, or of additional intervention /ID-19 exposure risk of noperative treatment npared with surgery**	Not applicable/ significantly		worse		Significantly
noperative treatment npared with surgery**	applicable/ significantly	Somewhat worse	Equivalent	Somewhat better	
Ade vr					
	< 20	20–50	51–69	70–79	≥ 80
Fall risk	High risk	Moderate risk		Minimal risk	No fall risk
e of pain or poor QOL (i.e., diplopia)	Extreme distress or discomfort	Moderate distress or discomfort		Low distress or discomfort	No distress or discomfort
ial factors complicating care**	Significant social factors	Few social factors			No social facto
disease (asthma, COPD, CF)	None	-	—	Minimal (rare inhaler)	> Minimal
structive sleep apnea	Not present	—	—	Mild/moderate (no CPAP)	On CPAP
sease (HTN, CHF, CAD)	None	Minimal (no meds)	Mild (≤ 1 med)	Moderate (2 meds)	Severe (≥3 meds)
Diabetes	None	_	Mild (no meds)	Moderate (PO meds only)	> Moderate (insulin)
nmunocompromised	No			Moderate	Severe
ymptoms (fever, cough, re throat, body aches, diarrhea)	None (asymptom- atic)	—	—	—	Yes
sure to known COVID-19 tive person in past 14 d	No	Probably not	Possibly	Probably	Yes
	care** disease (asthma, COPD, CF) structive sleep apnea sease (HTN, CHF, CAD) Diabetes munocompromised mptoms (fever, cough, re throat, body aches, diarrhea) sure to known COVID-19 tive person in past 14 d f daily living; CAD = coronary an us positive airway pressure; CV	care** social factors disease (asthma, COPD, CF) None structive sleep apnea Not present sease (HTN, CHF, CAD) None Diabetes None nmunocompromised No rmptoms (fever, cough, diarrhea) None sure to known COVID-19 No tive person in past 14 d No	care** social factors disease (asthma, COPD, CF) None — structive sleep apnea Not present — sease (HTN, CHF, CAD) None Minimal (no meds) Diabetes None — nmunocompromised No — re throat, body aches, diarrhea) (asymptom- atic) — sure to known COVID-19 No Probably not tive person in past 14 d To another the server of the server	care** social factors disease (asthma, COPD, CF) None — — structive sleep apnea Not present — — sease (HTN, CHF, CAD) None Minimal (no meds) Mild (≤ 1 med) Diabetes None — Mild (no meds) nmunocompromised No — — re throat, body aches, diarrhea) (asymptom- atic) — — sure to known COVID-19 No Probably not Possibly tive person in past 14 d f daily living; CAD = coronary artery disease; CF = cystic fibrosis; CHF = congestive heart failure; COPD = us positive airway pressure; CV = cardiovascular; GA = general anesthesia; HTN = hypertension; ILI = influ	care** social factors disease (asthma, COPD, CF) None — — Minimal (rare inhaler) structive sleep apnea Not present — — Mild/moderate (no CPAP) sease (HTN, CHF, CAD) None Minimal (no meds) Mild (≤ 1 med) Moderate (2 meds) Diabetes None — Mild (no meds) Moderate (PO meds only) nunnocompromised No Moderate /mptoms (fever, cough, diarrhea) None — — sure to known COVID-19 No Probably not Possibly Probably tive person in past 14 d No Probably not Possibly Probably sure to known COVID-19 is positive airway pressure; CV = cardiovascular; GA = general anesthesia; HTN = hypertension; ILI = influenza like illness; LOS = letonic obstructive pulmonic is positive airway pressure; CV = cardiovascular; GA = general anesthesia; HTN = hypertension; ILI = influenza like illness; LOS = letonic obstructive pulmonic is positive airway pressure; CV = cardiovascular; GA = general anesthesia; HTN = hypertension; ILI = influenza like illness; LOS = letonic obstructive pulmonic is positive airway pressure; CV = cardiovascular; GA = general anesthesia; HTN = hypertension; ILI = influenza like illness; LOS = letonic obstructive pulmonic is positive airway pressure; CV = cardiovascular; GA = general anesthesia; HTN = hypertension; ILI = influenza like illness; LOS = letonic obstructive

with COVID-19. We have modified this tool to be relevant and applicable to all subspecialties within ophthalmology while still preserving the factors that contribute to poorer outcomes, risk of virus transmission and demand on the health care system. The tool aligns with the 7 ethical principles of decision making — utility, fairness, equity, giving priority to the worst off, autonomy, minimizing harm and harmony² — and provides standardized decision making both within and across institutions.

The adapted tool (Table 1) preserves the 3 categories of procedure, patient and disease factors, while maintaining the same number of questions, which allows for comparison among surgical specialties using the original MeNTS system. Thirteen of the questions were unchanged from the original MeNTS system and 8 were modified, as these were not relevant to ophthalmic surgery. Each question is graded on a 5-point scale, with higher numbers associated with increased risk of COVID-19 or less urgency; for example, a monocular patient would have higher priority and therefore a lower score.

Procedure factors take into consideration the sequestration of OR resources, exposure of patient and hospital personnel to COVID-19, and potential postoperative resources that could be required. Because many ophthalmic procedures are performed under topical or local anesthetic, the need for intubation for general anesthesia was incorporated as a key factor in decreasing priority based on risk associated with aerosolizing procedures.

Disease factors consider the impact on patient outcomes from delayed surgical care or nonoperative care being significantly less effective, not an option, or potentially resulting in increased risk of COVID-19 exposure to the patient; for example, increased number of in-person office visits. To tailor this to our specialty, we incorporated a factor to account for visual impairment that hinders the ability to function or childhood development. Other important considerations were to prioritize conditions that would cause irreversible vision loss if not operated on urgently, and risk for significant vision loss if surgery was delayed for at least 6 weeks.

Finally, patient factors consider conditions with known association of greater severity of COVID-19 illness, such as advanced age, lung and cardiovascular disease, and an immune-compromised state. This category captures instances in which there is a greater likelihood that the patient has COVID-19 when their infection status is not known. Our adaptation of the tool included the addition of a category for risk of falls due to vision impairment, as this causes substantial morbidity and strain on the patient and health care system in the long term. We also consider the impact of ophthalmic disease on the patient's quality of life and whether or not there are social factors that may complicate their care.

CONCLUSION

The COS has provided a framework for surgical case prioritization in the context of the COVID-19 pandemic that, in addition to medical necessity and risk for COVID-19 transmission, systematically integrates factors that are unique to vision and eye care. This has provided guidance to Canadian ophthalmologists to facilitate decision making, triage for elective procedures and transparency in allocation of scarce OR resources.

Affiliations: From the Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC (Teja, Yin); the Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS (Mann); the Department of Ophthalmology and Visual Sciences, University of Western Ontario (Hooper); and the Department of Ophthalmology and Visual Sciences, University of Toronto (Buys).

Competing interests: None declared.

Contributors: All authors contributed substantially to the conception, writing and revision of this article and approved the final version for publication.

Content licence: This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons. org/licenses/by-nc-nd/4.0/

References

- 1. Strata Decision Technology. National Patient and Procedure Volume Tracker. Version 5.11.2020.
- Weih LM, Hassell JB, Keeffe J. Assessment of the impact of vision impairment. *Invest Ophthalmol Vis Sci* 2002;43:927-35.
- Prachand VN, Milner R, Angelos P, et al. Medically Necessary, Time-Sensitive Procedures: scoring system to ethnically and efficiently manage resource scarcity and provider risk during the COVID-19 pandemic. *J Am Coll Surg* 2020;231:281-288.